Positive expression levels of the biomarker were more common in adenocarcinoma than in squamous cell carcinoma, among patients who had non–small cell lung cancer (NSCLC). New research has identified a ...

By Sahil Pandey and Puyaan Singh Feb 27 (Reuters) - The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy for children with a rare genetic disorder that causes ...

Achondroplasia, also known as short-limb dwarfism, is associated with neurological symptoms and complications due to ...

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413 Conclusion: The FGFR3 ...

Credit: Getty Images. Erdafitinib produced responses in 94% of patients with intermediate-risk, FGFR3-mutant NMIBC in the phase 2 THOR-2 trial. Erdafitinib has demonstrated “promising antitumor ...

As of August 15, 2024, the data cutoff date, 41 patients were enrolled in the Phase 1 portion of the SURF301 Phase 1/2 study. Eligible participants were adults with advanced malignancies with or ...

SA family fights for five-year-old Frederick’s access to rare growth therapy, highlighting treatment barriers and costs.

Barcelona, Spain: Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a phase I clinical trial of an investigational drug, TYRA-300.

Precision medicine in GU cancers is evolving with biomarkers like BRCA1/2 mutations influencing PARP inhibitor use and pembrolizumab's tumor-agnostic approval for microsatellite instability. FGFR3 ...

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...

Researchers from The University of Osaka have developed a mouse model for achondroplasia. The model identified the importance ...